KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-cash Items (2016 - 2022)

Abbott Laboratories' Non-cash Items history spans 14 years, with the latest figure at $1.4 billion for Q1 2022.

  • For Q1 2022, Non-cash Items fell 18.32% year-over-year to $1.4 billion; the TTM value through Mar 2022 reached $1.4 billion, down 18.32%, while the annual FY2021 figure was $20.4 million, 98.69% down from the prior year.
  • Non-cash Items for Q1 2022 was $1.4 billion at Abbott Laboratories, up from $20.4 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $1.8 billion in Q1 2021 and bottomed at $996.0 in Q4 2018.
  • The 5-year median for Non-cash Items is $1.1 billion (2019), against an average of $847.2 million.
  • The largest annual shift saw Non-cash Items crashed 100.0% in 2018 before it soared 114256928.11% in 2019.
  • A 5-year view of Non-cash Items shows it stood at $996.0 in 2018, then skyrocketed by 114256928.11% to $1.1 billion in 2019, then skyrocketed by 36.82% to $1.6 billion in 2020, then plummeted by 98.69% to $20.4 million in 2021, then surged by 6987.68% to $1.4 billion in 2022.
  • Per Business Quant, the three most recent readings for ABT's Non-cash Items are $1.4 billion (Q1 2022), $20.4 million (Q4 2021), and $1.6 billion (Q3 2021).